Abstract:Background: Adenosine Deaminase (ADA) plays a critical role in purine metabolism and immune function. Its genetic and molecular characterization is essential for understanding its involvement in various physiological and pathological processes. The ADA gene has been implicated in immune system disorders and offers a potential target for therapeutic intervention. Objective: This study aims to comprehensively analyze the ADA gene and its protein product, detailing the genetic structure, physiochemical properties, subcellular localization, expression patterns, clinical variations, functional domains, splice variants, and potential as a drug target, to enhance the understanding of its function in human health. Methods: We utilized an array of in silico tools for gene sequence retrieval, including analysis of genomic databases for ADA's chromosomal location and gene structure. Physiochemical properties were determined using ProtParam, and subcellular localization was predicted with CELLO v.2.5. Gene expression levels across various tissues were ascertained using the Archive Ensemble TOOL. Clinical variations were categorized based on their potential pathogenicity, while splice variants and functional domains were predicted using domain-specific databases. Post-translational modifications were analyzed with prediction tools from the CBS server, and the STRING database facilitated protein interaction network analysis. Additionally, the DoG-Site Scorer predicted ADA's druggability profile. Results: ADA was localized to chromosome 12 (20q13.12), comprising 45940 base pairs encoding 363 amino acids. The protein's molecular weight was calculated as 37948.09, with a total atom count of 5396. Predictive localization indicated periplasmic and cytoplasmic presence with reliability scores of 1.437*, 1.210*, and 1.058*. Expression profiling revealed high ADA levels in the duodenum, with a notable expression in the lymphatic node. Clinical variations identified included 21 insertions and 23 inversions, with two pathogenic instances. Splice variant analysis predicted nine sites, and drug-binding potential was identified with scores as high as 0.81. Conclusion: Our study provides a detailed analysis of ADA, highlighting its genetic complexity and biological significance. The identification of clinically relevant gene variations and drug-binding pockets offers potential pathways for therapeutic intervention, emphasizing the importance of ADA in medical research and treatment strategies.

Comprehensive analysis of ADA2 genetic variants and estimation of carrier frequency driven by a function-based approach

Carrier Frequency and Incidence Estimation of Deficiency of Adenosine Deaminase 2 in the Chinese Population Based on Massive Exome Sequencing Data

Deficiency of Adenosine Deaminase 2 (DADA2): Hidden Variants, Reduced Penetrance, and Unusual Inheritance

Genotype and Functional Correlates of Disease Phenotype in Deficiency of Adenosine Deaminase 2 (DADA2).

Comparison of disease phenotypes and mechanistic insight on causal variants in patients with DADA2

A Cohort Study on Deficiency of ADA2 from China

Human ADA2 deficiency is characterized by the absence of an intracellular hypoglycosylated form of adenosine deaminase 2

A case report on deficiency of adenosine deaminase 2 with relapse–remission course and analysis of genotype–phenotype correlation

Dominant negative ADA2 mutations cause ADA2 deficiency in heterozygous carriers

Disrupted N-linked Glycosylation As a Disease Mechanism in Deficiency of ADA2.

Clinical Symptoms, Laboratory Parameters and Long-Term Follow-up in a National DADA2 Cohort

Evaluation and Management of Deficiency of Adenosine Deaminase 2: an International Consensus Statement.

In-silico Analysis of Adenosine Deaminase: From Gene Sequence Retrieval to Clinical Implications and Drug Targets

Adenosine Deaminase 2 Deficiency (DADA2): A Crosstalk Between Innate and Adaptive Immunity

Deficiency of Adenosine Deaminase 2 in Adults and Children: Experience From India

Early bone marrow alterations in patients with adenosine deaminase 2 deficiency across disease phenotypes and severities

Genotype and Phenotype of Adenosine Deaminase 2 Deficiency: a Report from Saudi Arabia

Deficiency of Adenosine Deaminase 2 in Adult Siblings: Many Years of a Misdiagnosed Disease with Severe Consequences

ADA2 is a lysosomal deoxyadenosine deaminase acting on DNA involved in regulating TLR9-mediated immune sensing of DNA

ELISA based assays to measure adenosine deaminases concentration in serum and saliva for the diagnosis of ADA2 deficiency and cancer

Human ADA2 Deficiency: Ten Years Later